BIOTHERYX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.biotheryx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Biotheryx, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT06515470
- Locations
- 🇺🇸
Biotheryx Investigative Site, Fairfax, Virginia, United States
A Study of BTX-1188 in Subjects With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Advanced Solid TumorNon Hodgkin LymphomaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Biotheryx, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05144334
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
News
No news found